"We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.”
​
George W. Merck
miSerumdx - Early Detection for Oral Cancer
Patients with oral cancers are usually diagnosed late in the disease with advance tumours. These patients often have high treatment related morbidity and only a 50% survival rate after 5 years.
The solution is early detection.
miSerumdx™, is a blood based diagnostic product for the early detection of oral cancers.
Early detection using miSerumdx™ will result in early intervention.
This will empower consumers, our patients to plan effective treatments, improve their quality of life, and significantly reduce therapy cost.
We have patents file in Australia, China, US and the EU. For more information please contact Dr Nham Tran (nham.tran@uts.edu.au)
​Empowering those who need it most
Blood Based Diagnostic
The miSerumdx™ suite of small RNA markers are found in the serum. Due to their structure they will not degrade in blood sampling.
QPCR Assay
The serum markers are detected with high sensitivity and specificity. We have developed a qPCR assay measuring the specific amounts of these markers in the blood.
Consultation with health professionals
miSerumdx™ has the potential to shift the current diagnostic approach for Oral Cancer. miSerumdx™ can diagnose patients much earlier, resulting in early intervention and treatment